Adlon Therapeutics L.P. and the Prescription Drug Safety Network Launch New Resources to Encourage Safe and Responsible Use of Prescription Stimulant Medications
Adhansia XR™ (methylphenidate HCl) Extended Release Capsules CII, New ADHD Treatment from Adlon Therapeutics L.P., Now Available Throughout the U.S.
Christian Mazzi, MD, BSBA/BA, MBA Named President and Executive Medical Director, Adlon Therapeutics L.P.
Adlon Therapeutics L.P. To Provide Funding Opportunities for Research to Expand Understanding of ADHD
Adlon Therapeutics L.P. Announces FDA Approval for Adhansia XR™ (Methylphenidate HCL) Extended-release Capsules CII for the Treatment of ADHD